Table 1.
Patient clinicopathological features.
| Clinical Data | Category | Patients (Frequency) |
|---|---|---|
| Gender | Male | 50 (54.3%) |
| Female | 42 (45.7%) | |
| Alive | 69 (75.0%) | |
| Status follow-up | Deceased | 23 (25.0%) |
| Age | Average (min-max) | 58 (20–81) |
| I/II | 60 (65.2%) | |
| Clinical stage | III/IV | 32 (44.8%) |
| T | T1a-b | 47 (51.1%) |
| T2a-b | 23 (25.0%) | |
| T3a-c | 17 (18.5%) | |
| T4 | 5 (5.4%) | |
| N0 | 77 (83.7%) | |
| N1 | 9 (9.8%) | |
| N | Nx | 6 (6.5%) |
| M | M0 | 75 (81.5%) |
| M1 | 17 (18.5%) | |
| <7 cm | 58 (63.0%) | |
| Tumor size | ≥7 cm | 34 (37.0%) |
| Furhman Grade | 1 | 20 (21.7%) |
| 2 | 49 (53.3%) | |
| 3 | 16 (17.4%) | |
| 4 | 7 (7.6%) | |
| White | 64 (69.6%) | |
| Black | 3 (3.3%) | |
| Yellow | 1 (1.0%) | |
| Brown * | 20 (21.7%) | |
| Self-Declared Ethnicity | Unknown | 4 (4.4%) |
| Systemic Therapy | Sunitinib | 12 (13.0%) |
| Interferon | 4 (4.3%) | |
| Pazopanib | 1 (1.1%) | |
| None | 74 (80.4%) | |
| Other | 1 (1.1%) | |
| Alive without disease | 64 (69.6%) | |
| Alive with disease progression | 2 (2.1%) | |
| Progression and death from the disease | 18 (19.6%) | |
| Disease status (last follow-up) | Died without disease recurrence | 8 (8.7%) |
* Brown = Brazilian mixed; T = size or direct extent of the primary tumor; N = degree of spread to regional. lymph nodes; M = presence of distant metastasis.